Nov 13 (Reuters) - German drugmaker BioNTech

has agreed to acquire Chinese biotech company Biotheus to

support its oncology strategy and gain full global rights to the

bispecific antibody candidate BNT327, it said on Wednesday.

BNT327 has been tested in clinical trials with tumour

patients, and Biotheus previously held the rights to

commercialize it in the Greater China market.

Under the terms of the agreement, BioNTech will pay 800

million dollars for 100% of the issued share capital, with

additional milestone payments of up to 150 million dollars.

The transaction is expected to close in the first quarter of

2025.